Amiodarone

Amiodarone is an iodine-rich benzofuran derivative whose structure resembles the thyroid hormone thyroxine, a similarity that helps explain some of its side effects. It is grouped with the class III antiarrhythmics, drugs that lengthen the recovery period of heart cells by blocking potassium channels, but amiodarone is unusual in that it also blocks sodium and calcium channels and weakly blocks beta-adrenergic receptors ^[1]. This broad action makes it one of the most effective and versatile rhythm-control drugs, while also complicating its behavior in the body ^[1].

The drug is used mainly for dangerous ventricular arrhythmias such as ventricular tachycardia and ventricular fibrillation, and for restoring or maintaining normal rhythm in atrial fibrillation. It is also part of resuscitation protocols for cardiac arrest with a shockable rhythm, although systematic reviews have found that antiarrhythmic drugs, including amiodarone, do not clearly improve survival to hospital discharge or long-term neurological outcome in that setting ^[2]. It can be given by mouth for long-term control or intravenously when a rapid effect is needed.

Amiodarone is highly fat-soluble and accumulates extensively in body tissues, including fat, liver, lung, and skin. As a result it has an exceptionally long half-life, often measured in weeks to months, so its effects build up slowly after treatment begins and persist long after it is stopped ^[1]. It is broken down in the liver to an active metabolite, and it strongly inhibits liver enzymes that process other drugs, leading to important interactions with medicines such as warfarin, digoxin, and certain statins ^[1].

Long-term use carries a substantial burden of adverse effects, which is why patients are monitored regularly. The most serious is lung injury, ranging from a usually silent accumulation of fat-laden cells to potentially fatal interstitial lung disease and fibrosis ^[4]. Because of its iodine content, amiodarone commonly disturbs thyroid function, causing either underactivity or overactivity of the gland; the overactive form, amiodarone-induced thyrotoxicosis, comes in two types that require different treatment ^[3]. Other recognized effects include liver enzyme abnormalities, near-universal but usually harmless corneal deposits, a blue-gray discoloration of sun-exposed skin, heightened sensitivity to sunlight, nerve damage, and slowing of the heart ^[1].

Amiodarone was first developed in the early 1960s and was initially used to treat angina before being withdrawn and later reintroduced once its antiarrhythmic value was recognized; it received United States approval in the mid-1980s ^[1]. It is a prescription-only medicine, included on the World Health Organization's list of essential medicines, and is available as oral tablets and as a solution for intravenous infusion.

Amiodarone is prescription only and demands monitoring because of its wide reach. It can scar the lungs, tip the thyroid into overactivity or underactivity because of its iodine, raise liver enzymes, leave harmless deposits in the cornea that cause visual halos, and turn sun-exposed skin a blue-gray shade. It can slow the heart too much and, less often than expected, prolong the QT interval. It has major interactions, raising levels of warfarin, digoxin and simvastatin, so those doses are usually cut. Routine checks of thyroid, liver, lung and eye health are part of long-term use.

Amiodarone interacts with almost everything, and a terminal half-life of roughly two months means those interactions persist for a long time after it is stopped.

It inhibits CYP3A4, CYP2C9, CYP2D6 and P-glycoprotein. Warfarin is the classic case: CYP2C9 inhibition raises INR substantially, and bleeding follows where it is not anticipated. Digoxin concentrations climb sharply through P-glycoprotein inhibition, bringing nausea, visual disturbance and arrhythmia. Simvastatin and lovastatin accumulate enough to cause myopathy and rhabdomyolysis.

Amiodarone prolongs the QT interval, so combining it with class Ia or other class III antiarrhythmics, fluoroquinolones, macrolides, azoles or antipsychotics raises the risk of torsades de pointes.

Beta blockers and non-dihydropyridine calcium channel blockers add to its suppression of the sinus and AV nodes, producing bradycardia, sinus arrest or complete heart block. Sofosbuvir-containing hepatitis C regimens caused severe symptomatic bradycardia in post-marketing reports, an effect still not fully explained.

Checking a whole stack? Run it through interactions + stacks.

Amiodarone was first synthesized in Belgium by the Labaz laboratories in 1961 and was originally marketed as an antianginal agent, valued for its coronary-vasodilating properties. Its powerful antiarrhythmic action was recognized later, and the pharmacologist Bramah Singh's work in the early 1970s helped define it as the prototype of the class III antiarrhythmic drugs, those that prolong cardiac repolarization. It came into widespread cardiological use through the 1980s and received United States Food and Drug Administration approval in 1985. Despite an extensive and sometimes troublesome side-effect profile, it has remained one of the most effective and frequently used antiarrhythmic drugs available.

Amiodarone is widely regarded as among the most effective antiarrhythmic drugs, often succeeding in maintaining normal rhythm where other agents fail, including in patients with heart failure and reduced left ventricular function, in whom pooled analyses of the AFFIRM and AF-CHF trials showed it worked comparably well. Cardiologists respect it both for controlling life-threatening ventricular arrhythmias and for managing atrial fibrillation. That effectiveness is balanced against a well-documented need for caution: its intense tissue accumulation and iodine content can affect the lungs, thyroid, liver, eyes, and skin, and its unusually long half-life means effects and side effects persist for weeks. For this reason it is typically used under careful monitoring, reserved for situations where its benefits clearly outweigh the risks.